Clinical Trials Browser

Phase 3 × Recruiting × Adenocarcinoma × Clear all

Adenocarcinoma, Uterine Cervical Neoplasms, Carcinoma, Adenosquamous

NCT06592924 2026-04-14

TRIPLE-SWITCH

Phase 3 Recruiting

830 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT07431281 2026-04-13

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Phase 3 Recruiting

2,130 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT06901531 2026-04-03

LUCERNA

Phase 3 Recruiting

500 enrolled

Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT07023315 2026-02-11

A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

Phase 3 Recruiting

760 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Phase 3 Recruiting

300 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT06177041 2024-02-28

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Phase 3 Recruiting

486 enrolled

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT05264896 2023-09-07

Perioperative FLOT vs Adjuvant XELOX for CA Stomach

Phase 3 Recruiting

110 enrolled

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

Clinical Trials

PAROLA

TRIPLE-SWITCH

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

LUCERNA

A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Perioperative FLOT vs Adjuvant XELOX for CA Stomach